Comprehensive genomic surveillance analysis of SARS-CoV-2: Global epidemic dynamics and geographic variability of variants
Almost 4 years into the COVID-19 pandemic, the world has shifted into a phase characterized by the Omicron variant, which has maintained prevalence for over a year, giving rise to more than 3690 subvariants globally. To investigate the worldwide genomic surveillance of SARS-CoV-2, metadata from over 5.5 million high-quality genomes were analyzed. The results revealed significant geographic heterogeneity in the distribution of variants of concern/interest (VOC/VOI) across different continents, especially noticeable for the Epsilon and Iota VOIs. Moreover, the sequencing turnaround times exhibited notable geographic heterogeneity. These disparities in turnaround time and geographic coverage are critical for refining policies, guidelines, and mitigation strategies to effectively address the COVID-19 pandemic. In the context of the persistent COVID-19 pandemic and the global spread of various variants, understanding the mortality and transmissibility rates of SARS-CoV-2 is crucial. The mean mortality rate of SARS-CoV-2 stands at 2.62% (median: 2.17%; 95% confidence interval [CI]: 1.06 – 6.81%). Notably, the Omicron variant exhibits distinct transmissibility characteristics (mean: 13.22; median: 12.06; 95% CI: 6.02 – 20.59) compared to other SARS-CoV-2 variants (mean: 1.40; median: 1.12; 95% CI: 0.97 – 2.28). These data underscore the need for future genomic surveillance strategies, including strategic sampling, randomized baseline surveillance, and rapid reporting, to enhance global public health efforts. Such strategies are essential for monitoring and responding to the evolving landscape of the pandemic, as evidenced by the variability in mortality and transmission rates among different variants.
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733. doi: 10.1056/NEJMoa2001017
- Brito AF, Semenova E, Dudas G, et al. Global disparities in SARS-CoV-2 genomic surveillance. Nat Commun. 2022;13:7003. doi: 10.1038/s41467-022-33713-y
- Pilapil JD, Notarte KI, Yeung KL. The dominance of co-circulating SARS-CoV-2 variants in wastewater. Int J Hyg Environ Health. 2023;253:114224. doi: 10.1016/j.ijheh.2023.114224
- Ong SW, Chia T, Young BE. SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. Expert Rev Respir Med. 2022;16:499-502. doi: 10.1080/17476348.2022.2057299
- Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall. 2017;1:33-46. doi: 10.1002/gch2.1018
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533-534. doi: 10.1016/S1473-3099(20)30120-1
- Obermeyer F, Jankowiak M, Barkas N, et al. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science. 2022;376:1327-1332. doi: 10.1126/science.abm1208
- CaoY, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657-663. doi: 10.1038/s41586-021-04385-3
- Cui Z, Liu P, Wang N, et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 omicron. Cell. 2022;185:860-871.e13. doi: 10.1016/j.cell.2022.01.019
- Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593-602. doi: 10.1038/s41586-022-04980-y
- Cao Y, Song W, Wang L, et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe. 2022;30:1527-1539.e5. doi: 10.1016/j.chom.2022.09.018
- Jian F, Yu Y, Song W, et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. Lancet Infect Dis. 2022;22:1535-1537. doi: 10.1016/S1473-3099(22)00642-9